Application Nr Approved Date Route Status External Links
BLA761035 None Intravenous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage • Empliciti Is Indicated In Combination With Lenalidomide And Dexamethasone For The Treatment Of Adult Patients With Multiple Myeloma Who Have Received One To Three Prior Therapies. • Empliciti Is Indicated In Combination With Pomalidomide And Dexamethasone For The Treatment Of Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Therapies Including Lenalidomide And A Proteasome Inhibitor. Empliciti Is A Slamf7-Directed Immunostimulatory Antibody Indicated In • Combination With Lenalidomide And Dexamethasone For The Treatment Of Adult Patients With Multiple Myeloma Who Have Received One To Three Prior Therapies. (1) • Combination With Pomalidomide And Dexamethasone For The Treatment Of Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Therapies Including Lenalidomide And A Proteasome Inhibitor. (1)

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Elotuzumab

Comments